Results analysis from Kepler Trust Intelligence

RNS Number : 2503S

Bellevue Healthcare Trust PLC

13 July 2022

 

Bellevue Healthcare (BBH)

13/07/2022

Results analysis from Kepler Trust Intelligence

Bellevue Healthcare (BBH) has reported its interim results for the six months to 31 May 2022, a period in which the board resolved to change the name from 'BB Healthcare Trust plc' to 'Bellevue Healthcare Trust plc'. Over the period, the share price and NAV decreased 17.5% and 18.7% respectively. Including the final dividend for the financial year ended 2021, the company's shares delivered a total return of -16.1%. In comparison, the MSCI World Healthcare Index delivered a total return in sterling of +4.5%. Since inception, BBH has delivered a NAV total return of 79.3%, which is 15.5% behind the MSCI World Healthcare Index return of 94.8%. The managers have been gradually 'buying the dip' and increasing the gross exposure of the company by increasing the gearing. The leverage ratio stood at 11.5% as of May 2022.

Kepler View

BBH's managers are fundamental stock pickers, and pay little attention to benchmarks when constructing the portfolio. As a result, one might imagine that performance will deviate from indices. As of 31 May 2022, BBH's portfolio consisted of 15.1% mega-cap companies and 8.5% large-cap companies. In contrast, the MSCI World Healthcare Index consisted of 76.2% mega-cap and 21.7% large-cap. This small-cap exposure has left the portfolio very much out of favour, which has contributed to the short-term underperformance relative to the healthcare index. This is a departure from the longer-term picture, as we illustrate in our February research note . Prior to 2022, on a rolling three-year basis, BBH has been consistently ahead of the index and therefore in line with its investment objective.

We think it instructive that the managers report that they are seeing a divergence between share prices and operating performance. As one might expect from stock pickers, the managers are reacting. The interims highlight that the team have been "taking advantage of the current weakness to re-establish some exposure to the dental sector…[and] added to our holdings in the diagnostics, healthcare technology, tools and services holdings". This has been funded by sales of companies in "managed care and diversified therapeutics, which have held up well on a relative basis".

CLICK HERE TO READ THE FULL REPORT

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

Important information

This report has been issued by Kepler Partners LLP.  The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.  

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

END

 

 

NRADBGDRCSBDGDD